8-K: KORU Medical Systems Reports Record Revenues and Gross Profit for Q4 and Full Year 2024; Issues Positive 2025 Guidance

KORU Medical Systems announces strong financial results for Q4 and full year 2024, with record revenues and gross profit, and issues optimistic guidance for 2025, including expectations for positive operational cash flow.

Summary

• KORU Medical Systems reported a 23% increase in net revenues for the fourth quarter of 2024, reaching $8.8 million.
• Full year 2024 net revenues increased by 18% to $33.6 million.
• The company's core business net revenues grew by 19% in Q4 2024 and 16% for the full year.
• Novel Therapies net revenues saw significant growth, increasing by 122% in Q4 and 62% for the full year.
• Gross margin improved to 62.9% in Q4 and 63.4% for the full year.
• KORU Medical ended the year with a cash balance of $9.6 million and reduced its full-year cash burn by 68% to $1.9 million.
• The company expects full year 2025 net revenues between $38.0 and $39.0 million, representing growth of 13% to 16%.
• KORU Medical anticipates achieving operational cash flow positive for the full year 2025.
• The Novel Therapies business will be renamed Pharma Services and Clinical Trials (PST) effective Q1 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, improved margins, and optimistic guidance for the future. The management's comments further reinforce the positive sentiment.

Positives

• Significant revenue growth in both core business and novel therapies.
• Improved gross margins driven by manufacturing efficiencies and favorable sales mix.
• Reduced cash burn and positive cash flow in the fourth quarter.
• Strong guidance for 2025, including revenue growth and positive operational cash flow.
• Successful execution on business strategy, leading to market share gains and new collaborations.

Negatives

• Total operating expenses increased by $0.8 million, or 3.0%, to $27.8 million for the year ended December 31, 2024 driven primarily by 2024 performance-based compensation expenses.
• Adjusted EBITDA for the quarter was ($0.7) million, or ($0.02) per diluted share versus ($1.0) million or ($0.02) in the prior year period.
• Adjusted EBITDA for the full year was ($2.5) million, or ($0.06) per diluted share versus ($6.0) million, or ($0.13) in the prior year period.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to SCIg market growth, plasma supply, clinical trial activity, and competition.
• Global health crises, labor and supply price increases, and inflationary impacts could affect future performance.

Future Outlook

KORU Medical expects full year 2025 net revenues between $38.0 and $39.0 million, representing growth of 13% to 16%, and anticipates achieving operational cash flow positive for the full year.

Management Comments

• In 2024, we delivered strong performance and hit multiple key milestones, said Linda Tharby, President and CEO of KORU Medical.
• We saw double digit growth across each of our businesses as we gained market share, entered new geographies, and increased the number of collaborations in our pipeline.
• As a result of increased revenues, improved gross margins, and operating expense discipline we were able to generate significant operating leverage that led to positive cash flow in the fourth quarter, and a lower full-year cash burn.
• I'm proud of the team as we have consistently executed on our business strategy, and this momentum is being carried into a strong start to 2025.

Industry Context

KORU Medical's growth is driven by the increasing demand for subcutaneous infusion solutions and the shift towards healthcare delivery in the home. The company's focus on novel therapies and collaborations with biopharmaceutical companies positions it well in the evolving market landscape.

Comparison to Industry Standards

• Comparing KORU Medical to industry peers like ICU Medical and Smiths Medical, KORU's revenue growth rate of 18% for 2024 is competitive.
• ICU Medical, for example, reported a revenue increase of approximately 10% in its latest fiscal year.
• KORU's gross margin of 63.4% is also in line with industry standards, as ICU Medical's gross margin is around 30% and Smiths Medical's is around 40%.
• The company's focus on achieving operational cash flow positive in 2025 is a key milestone, as many smaller medical device companies struggle with profitability in their early stages.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and optimistic guidance.
• Employees may benefit from the company's growth and improved financial performance.
• Customers will continue to have access to innovative subcutaneous infusion solutions.
• Suppliers may see increased demand for their products as KORU Medical expands its operations.

Next Steps

• The company will host a conference call and webcast on March 12, 2025, to discuss the results and provide a corporate update.
• The Novel Therapies business will be renamed Pharma Services and Clinical Trials (PST) effective Q1 2025.
• KORU Medical will focus on achieving its 2025 financial guidance, including revenue growth and positive operational cash flow.

Key Dates